Navigation Links
Lexicon's IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial

THE WOODLANDS, Texas, July 28, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it has successfully completed a Phase 1 clinical trial of LX1033, an orally-delivered small molecule drug candidate for diarrhea-predominant irritable bowel syndrome (IBS-d).  Lexicon plans to move LX1033 forward into a Phase 2 study in patients with IBS-d.

Top-line results demonstrated that LX1033 was well tolerated at all doses and produced a statistically significant reduction in serotonin synthesis compared to placebo, as measured by both plasma (p<0.001) and urinary (p<0.01) 5-hydroxyindoleacetic acid (5-HIAA), a biomarker for serotonin synthesis. Importantly, a greater reduction in serotonin synthesis was achieved with lower and less frequent dosing and at lower drug exposure levels than was observed with Lexicon's first generation serotonin synthesis inhibitor, LX1031, which had previously demonstrated clinical benefit to IBS patients in a Phase 2a clinical trial as measured by both global assessment of adequate relief and stool consistency.

"Based on the completed LX1033 Phase 1 program, we are confident that a convenient dose regimen of this compound can provide the level of serotonin reduction that we have previously associated with clinical benefit for patients with IBS-d," said Dr. Brian Zambrowicz, chief scientific officer at Lexicon.  "We were also impressed by the performance of the blood test for measuring 5-HIAA and anticipate using this biomarker to guide future drug development of LX1033."

The LX1033 Phase 1 trial was conducted as a randomized, placebo-controlled trial in healthy volunteers.  In the multiple ascending dose portion of the study, doses of 250 mg, 500 mg, and 750 mg given three times daily, as well as 1,000 mg given twice daily, were administered over the course of 14 days.  There were eight healthy volunteers (six receiving active compound, two receiving placebo) in each dose group.  Study endpoints included safety and tolerability together with pharmacokinetic and pharmacodynamic parameters consisting of measures of both plasma and urinary 5-HIAA.  Data from the study showed that LX1033 produced a statistically significant decrease in both plasma and urinary 5-HIAA as compared to placebo at all doses tested.  Notably, the plasma measures of 5-HIAA in the recent study were obtained from a simple morning blood draw and correlated with results obtained by the traditional 24-hour urine collection method.

"The favorable safety and tolerability profile for LX1033, together with its local site of action within the gastrointestinal tract and ability to potently reduce serotonin synthesis, make this a very attractive candidate for clinical trials in IBS-d, where the need for new treatments is great," said Dr. Pablo Lapuerta, senior vice president and chief medical officer at Lexicon.  "We look forward to advancing this drug into a Phase 2 trial where we can examine safety and efficacy in IBS-d."

About LX1033

LX1033 is an orally-delivered drug candidate for IBS that inhibits tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin.  LX1033 is designed to act locally in the gastrointestinal (GI) tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain.  

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031 and LX1033, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX1031 and LX1033. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031 and LX1033 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan
2. Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session
3. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
4. Arcion Therapeutics Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
5. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
6. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
7. Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
8. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
9. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
10. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
(Date:11/29/2015)... Nov. 29, 2015  Strengthening its leadership in connected ... PHIA) today announced IntelliSpace Portal 8.0 , the ... visualization platform that helps radiologists detect, diagnose and follow-up ... Radiological Society of North America Annual Meeting (RSNA) ... 8.0 helps address the changing demands in radiology that ...
(Date:11/29/2015)... -- The GE Health Cloud 1 was unveiled today at ... North America (RSNA) meeting in Chicago ... cloud ecosystem and its applications will connect radiologists and clinicians ... teams – both inside and outside the hospital setting. ... "As the digital industrial leader, we are betting big on ...
(Date:11/27/2015)... November 27, 2015 Une ... photodynamique au Bremachlorin contre le cancer avancé. ... à combiner l,immunothérapie au traitement photodynamique au Bremachlorin ... Une nouvelle approche consistant à combiner ... cancer avancé.    Clinical Cancer ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... Doctors who missed a case ... recognize the signs of mesothelioma and push for a diagnosis, especially in people exposed ... Click here to read it now. , Researchers at Gifu Prefectural ...
(Date:11/29/2015)... CA (PRWEB) , ... November 29, 2015 , ... Key ... is proud to announce their December, 2015, featured apartment community: Epic. In showcasing this ... corporate housing in the tight Bay Area rental market to efficiently find housing suitable ...
(Date:11/28/2015)... ... ... Trying to relax on a couch can actually be uncomfortable, so an inventor ... to personal experience with a bad back," he said. , This easy-to-use, versatile invention ... increases support. It also makes it easier to eat, do other activities and charge ...
(Date:11/27/2015)... ... November 28, 2015 , ... There is only one ... our billings from last year? , This question has not been an easy question ... to the retirement age and the younger workforce don’t share the same discipline around ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published November ... they are handling security in light of the recent terrorist attacks in Paris, other ... to stop an attack from reaching U.S. soil. Especially around special events that may ...
Breaking Medicine News(10 mins):